Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

EMA – New features further strengthen Priority Medicines scheme (PRIME)

EMA is introducing a number of new features to the PRIority Medicines (PRIME) scheme to strengthen its support for the development of medicines in areas of unmet medical needs.

The implementation of the new features follows a review of the first five years’ experience with the scheme, which highlighted some opportunities for further strengthening the scheme.

To optimise the early scientific and regulatory support provided to promising medicines, a roadmap for each PRIME development alongside a product development tracker will be established. Both tools will facilitate the continuous dialogue between regulators and developers as the progress of the development is continuously monitored and as critical aspects for further discussion can be identified throughout the development process.

Starting as a 12-month pilot until March 2024, expedited scientific advice can now be provided specifically for PRIME developments in case of issues with a specific development programme that has already received comprehensive initial advice. This agile setting for scientific advice will allow to address queries from PRIME applicants in a shorter timeframe.

The final new feature is represented by submission readiness meetings, which will be held approximately one year ahead of the submission of a marketing authorisation application with developers of PRIME medicines. The scope of these meetings is to discuss the status of the development including the implementation of previous regulatory advice, and the resulting data package intended to support the marketing authorisation application. Prospective applicants would also be expected to present mature plans for post-marketing evidence generation, as applicable.

More information on the EMA Website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (4 mai 2023). EMA – New features further strengthen Priority Medicines scheme (PRIME). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o69t


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.